Sight Sciences (SGHT) Cash from Financing Activities (2020 - 2026)
Sight Sciences' (SGHT) quarterly Cash from Financing Activities came in at $88000.0 in Q1 2026, up 450.0% year-on-year from $16000.0 in Q1 2025, and down 93.04% quarter-over-quarter from $1.3 million in Q4 2025.
Sight Sciences (SGHT) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Sight Sciences' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $88000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 450.0% year-over-year to $88000.0 in Q1 2026; TTM through Mar 2026 was $1.9 million, a 68.54% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 63.92% from the prior year.
- Cash from Financing Activities declined to $88000.0 in Q1 2026 per SGHT's latest filing, from $1.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $5.4 million in Q4 2024 and bottomed at -$942000.0 in Q1 2024.
- The 5-year median for Cash from Financing Activities is $158000.0 (2022), against an average of $540882.4.
- Biggest YoY gain for Cash from Financing Activities was 1333.24% in 2024; the steepest drop was 503.85% in 2024.
- Year by year, Cash from Financing Activities stood at $812000.0 in 2022, then slumped by 53.69% to $376000.0 in 2023, then soared by 1333.24% to $5.4 million in 2024, then plunged by 76.53% to $1.3 million in 2025, then tumbled by 93.04% to $88000.0 in 2026.
- Per Business Quant, the three latest SGHT Cash from Financing Activities figures stand at $88000.0 (Q1 2026), $1.3 million (Q4 2025), and $25000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Sight Sciences | 253.53 Mn | 168.57 Mn | 16.98 Mn | 88,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88,000.00 |
| Mar 31, 2026 | 88,000.00 |
| Dec 31, 2025 | 1.27 Mn |
| Dec 31, 2025 | 1.27 Mn |
| Sep 30, 2025 | 25,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 485,000.00 |
| Jun 30, 2025 | 485,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Mar 31, 2025 | 16,000.00 |
| Dec 31, 2024 | 5.39 Mn |
| Dec 31, 2024 | 5.39 Mn |
| Sep 30, 2024 | 76,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 441,000.00 |
| Mar 31, 2024 | -942,000.00 |
| Mar 31, 2024 | -942,000.00 |
| Dec 31, 2023 | 376,000.00 |
| Dec 31, 2023 | 376,000.00 |